TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance

eLife

Volumn 5, Issue JANUARY2016, 2016, Pages

  Baas, Marije ^a,b,c,g   Besançon, Alix ^a,b,c   Goncalves, Tania ^a,b,c   Valette, Fabrice ^a,b,c   Yagita, Hideo ^d   Sawitzki, Birgit ^e   Volk, Hans Dieter ^e   Waeckel Enée, Emmanuelle ^a,b,c   Rocha, Benedita ^a,f   Chatenoud, Lucienne ^a,b,c   You, Sylvaine ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c CNRS   (France)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f INSTITUT PASTEUR   (France)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; ANTIBODY; CD274 PROTEIN, MOUSE; CD3 ANTIGEN; PDCD1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; IMMUNOLOGICAL TOLERANCE; MICROARRAY ANALYSIS; MOUSE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET TRANSPLANTATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; UPREGULATION; ALLOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CLONAL ANERGY; IMMUNOLOGY; METABOLISM; PANCREAS ISLET; TRANSPLANTATION;

ALLOGRAFTS; ANIMALS; ANTIBODIES; ANTIGENS, CD274; ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CLONAL ANERGY; IMMUNE TOLERANCE; ISLETS OF LANGERHANS; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, ANIMAL; PROGRAMMED CELL DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION;

EID: 84956962773     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.08133     Document Type: Article

References (49)

1. Ayroldi E, Migliorati G, Cannarile L, Moraca R, Delfino DV, Riccardi C. 1997. CD2 rescues t cells from t-cell receptor/CD3 apoptosis: a role for the Fas/Fas-l system. Blood 89:3717-3726.
2. Baas MC, Besançon A, Sawitzki B, Mangez C, Valette F, Chatenoud L, You S. 2013. Intragraft mechanisms associated with the immunosuppressive versus the tolerogenic effect of CD3 antibodies in a mouse model of islet allografts. Transplantation Proceedings 45:1895-1898. doi: 10.1016/j.transproceed.2013.01.054.
3. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687. doi: 10.1038/nature04444.
4. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach J-F, Chatenoud L. 2003. TGF-b-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nature Medicine 9:1202-1208. doi: 10.1038/nm924.
5. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR. 1995. Cell-autonomous fas (cD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441-444. doi: 10.1038/373441a0.
6. Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson MA, Michaëlsson J, Lund O, Hejdeman B, Jansson M, Sönnerborg A, Koup RA, Betts MR, Karlsson AC, Luban J. 2014. T-bet and eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathogens 10:e1004251. doi: 10.1371/journal.ppat.1004251.
7. Celli S, Albert ML, Bousso P. 2011. Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy. Nature Medicine 17:744-749. doi: 10.1038/nm.2376.
8. Diamond AS, Gill RG. 2000. An essential contribution by IFN-to CD8+ t cell-mediated rejection of pancreatic islet allografts. The Journal of Immunology 165:247-255. doi: 10.4049/jimmunol.165.1.247.
9. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, Johnson RS, Goldrath AW. 2013. Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen. Nature Immunology 14:1173-1182. doi: 10.1038/ni.2714.
10. Doering TA, Crawford A, Angelosanto JM, Paley MA, Ziegler CG, Wherry EJ. 2012. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 37: 1130-1144. doi: 10.1016/j.immuni.2012.08.021.
11. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. 2009. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nature Immunology 10: 1185-1192. doi: 10.1038/ni.1790.
12. Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, Panteleyev AA, Okkenhaug K, Cantrell DA. 2012. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. Journal of Experimental Medicine 209:2441-2453. doi: 10.1084/jem.20112607.
13. Francisco LM, Sage PT, Sharpe AH. 2010. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews 236:219-242. doi: 10.1111/j.1600-065X.2010.00923.x.
14. Gorelik L, Flavell RA. 2000. Abrogation of TGFb signaling in t cells leads to spontaneous t cell differentiation and autoimmune disease. Immunity 12:171-181. doi: 10.1016/S1074-7613(00)80170-3.
15. Goto R, You S, Zaitsu M, Chatenoud L, Wood KJ. 2013. Delayed anti-CD3 therapy results in depletion of alloreactive t cells and the dominance of Foxp3(+) CD4(+) graft infiltrating cells. American Journal of Transplantation 13:1655-1664. doi: 10.1111/ajt.12272.
16. Gras S, Kjer-Nielsen L, Chen Z, Rossjohn J, McCluskey J. 2011. The structural bases of direct t-cell allorecognition: implications for t-cell-mediated transplant rejection. Immunology and Cell Biology 89:388-395. doi: 10.1038/icb.2010.150.
17. Haspot F, Fehr T, Gibbons C, Zhao G, Hogan T, Honjo T, Freeman GJ, Sykes M. 2008. Peripheral deletional tolerance of alloreactive CD8 but not CD4 t cells is dependent on the PD-1/PD-L1 pathway. Blood 112:2149-2155. doi: 10.1182/blood-2007-12-127449.
18. Hawiger D, Wan YY, Eynon EE, Flavell RA. 2010. The transcription cofactor hopx is required for regulatory t cell function in dendritic cell-mediated peripheral t cell unresponsiveness. Nature Immunology 11:962-968. doi: 10.1038/ni.1929.
19. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. New England Journal of Medicine 346:1692-1698. doi: 10.1056/NEJMoa012864.
20. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, Mullen AC, Gasink CR, Kaech SM, Miller JD, Gapin L, Ryan K, Russ AP, Lindsten T, Orange JS, Goldrath AW, Ahmed R, Reiner SL. 2005. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nature Immunology 6:1236-1244. doi: 10.1038/ni1268.
21. Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, Yagita H, Azuma M, Sharpe AH, Auchincloss H, Sayegh MH, Najafian N. 2005. Analysis of the role of negative t cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. The Journal of Immunology 174:6648-6656. doi: 10.4049/jimmunol.174.11.6648.
22. Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. 2000. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. The Journal of Immunology 164:512-521. doi: 10.4049/jimmunol.164.1.512.
23. Kang S-M, Beverly B, Tran A-C, Brorson K, Schwartz RH, Lenardot MJ. 1992. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 257:1134-1138. doi: 10.1126/science.257.5073.1134.
24. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology 26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331.
25. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin J-M, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach J-F, Pipeleers D, Chatenoud L. 2005. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. New England Journal of Medicine 352:2598-2608. doi: 10.1056/NEJMoa043980.
26. Kostelny SA, Cole MS, Tso JY. 1992. Formation of a bispecific antibody by the use of leucine zippers. Journal of Immunology 148:1547-1553.
27. Lucas CL, Workman CJ, Beyaz S, LoCascio S, Zhao G, Vignali DAA, Sykes M. 2011. LAG-3, TGF-, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. Blood 117:5532-5540. doi: 10.1182/blood-2010-11-318675.
28. Macián F, Garcıa-Cózar F, Im S-H, Horton HF, Byrne MC, Rao A. 2002. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109:719-731. doi: 10.1016/S0092-8674(02)00767-5.
29. Medoff BD, Wain JC, Seung E, Jackobek R, Means TK, Ginns LC, Farber JM, Luster AD. 2006. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. The Journal of Immunology 176:7087-7095. doi: 10.4049/jimmunol.176.11.7087.
30. Monk NJ, Hargreaves REG, Marsh JE, Farrar CA, Sacks SH, Millrain M, Simpson E, Dyson J, Jurcevic S. 2003. Fc-dependent depletion of activated t cells occurs through CD40L-specific antibody rather than costimulation blockade. Nature Medicine 9:1275-1280. doi: 10.1038/nm931.
31. Ochando JC, Krieger NR, Bromberg JS. 2006. Direct versus indirect allorecognition: visualization of dendritic cell distribution and interactions during rejection and tolerization. American Journal of Transplantation 6:2488-2496. doi: 10.1111/j.1600-6143.2006.01494.x.
32. Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff EK, Robertson EJ, Lauer GM, Reiner SL, Wherry EJ. 2012. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338:1220-1225. doi: 10.1126/science.1229620.
33. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, Banica M, DiCioccio CB, Gross DA, Mao CA, Shen H, Cereb N, Yang SY, Lindsten T, Rossant J, Hunter CA, Reiner SL. 2003. Control of effector CD8+ T cell function by the transcription factor eomesodermin. Science 302:1041-1043. doi: 10.1126/science.1090148.
34. Peixoto A, Evaristo C, Munitic I, Monteiro M, Charbit A, Rocha B, Veiga-Fernandes H. 2007. CD8 single-cell gene coexpression reveals three different effector types present at distinct phases of the immune response. Journal of Experimental Medicine 204:1193-1205. doi: 10.1084/jem.20062349.
35. Qian S, Lu L, Fu F, Li Y, Li W, Starzl TE, Fung JJ, Thomson AW. 1997. Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. Journal of Immunology 158:4654-4661.
36. Ribeiro-dos-Santos P, Turnbull EL, Monteiro M, Legrand A, Conrod K, Baalwa J, Pellegrino P, Shaw GM, Williams I, Borrow P, Rocha B. 2012. Chronic HIV infection affects the expression of the 2 transcription factors required for CD8 t-cell differentiation into cytolytic effectors. Blood 119:4928-4938. doi: 10.1182/blood-2011-12-395186.
37. Riella LV, Paterson AM, Sharpe AH, Chandraker A. 2012. Role of the PD-1 pathway in the immune response. American Journal of Transplantation 12:2575-2587. doi: 10.1111/j.1600-6143.2012.04224.x.
38. Rocha B, von Boehmer H. 1991. Peripheral selection of the t cell repertoire. Science 251:1225-1228. doi: 10.1126/science.1900951.
39. Rocha B, Tanchot C, Von Boehmer H. 1993. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. Journal of Experimental Medicine 177:1517-1521. doi: 10.1084/jem.177.5.1517.
40. Safford M, Collins S, Lutz MA, Allen A, Huang C-T, Kowalski J, Blackford A, Horton MR, Drake C, Schwartz RH, Powell JD. 2005. Egr-2 and egr-3 are negative regulators of T cell activation. Nature Immunology 6:472-480. doi: 10.1038/ni1193.
41. Schwartz RH. 2003. T cell anergy. Annual Review of Immunology 21:305-334. doi: 10.1146/annurev.immunol.21.120601.141110.
42. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG.Protégé Trial InvestigatorsInvestigators PT. 2011. Teplizumab for treatment of type 1 diabetes (prote´ ge´ study): 1-year results from a randomised, placebo-controlled trial. The Lancet 378:487-497. doi: 10.1016/S0140-6736(11)60931-8.
43. Sleater M, Diamond AS, Gill RG. 2007. Islet allograft rejection by contact-dependent CD8+ T cells: perforin and FasL play alternate but obligatory roles. American Journal of Transplantation 7:1927-1933. doi: 10.1111/j.1600-6143.2007.01889.x.
44. Sobek V, Balkow S, Körner H, Simon MM. 2002. Antigen-induced cell death of t effector cells in vitro proceeds via the fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes. European Journal of Immunology 32:2490-2499. doi: 10.1002/1521-4141(200209)32:9<2490::AID-IMMU2490>3.0.CO;2-G.
45. Sundstedt A, Sigvardsson M, Leanderson T, Hedlund G, Kalland T, Dohlsten M. 1996. In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa b transcription factors. Proceedings of the National Academy of Sciences of the United States of America 93:979-984. doi: 10.1073/pnas.93.3.979.
46. Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS. 2002. Cross-primed CD8(+) t cells mediate graft rejection via a distinct effector pathway. Nature Immunology 3:844-851. doi: 10.1038/ni831.
47. Williams MA, Bevan MJ. 2007. Effector and memory CTL differentiation. Annual Review of Immunology 25:171-192. doi: 10.1146/annurev.immunol.25.022106.141548.
48. Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X, Paterson AM, Watanabe T, Vanguri V, Yagita H, Azuma M, Blazar BR, Freeman GJ, Rodig SJ, Sharpe AH, Chandraker A, Sayegh MH. 2011. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. The Journal of Immunology 187:1113-1119. doi: 10.4049/jimmunol.1100056.
49. You S, Zuber J, Kuhn C, Baas M, Valette F, Sauvaget V, Sarnacki S, Sawitzki B, Bach J-F, Volk H-D, Chatenoud L. 2012. Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing. American Journal of Transplantation 12:2909-2919. doi: 10.1111/j.1600-6143.2012.04213.x.